These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 2693621

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study.
    Roila F, Basurto C, Minotti V, Ballatori E, Tonato M, Del Favero A.
    Oncology; 1988; 45(5):346-9. PubMed ID: 3412741
    [Abstract] [Full Text] [Related]

  • 4. Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules.
    Gez E, Strauss N, Vitzhaki N, Cass Y, Edelmann DZ.
    Cancer Chemother Pharmacol; 1992; 30(3):229-32. PubMed ID: 1628373
    [Abstract] [Full Text] [Related]

  • 5. Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo.
    Pollera CF, Nardi M, Marolla P, Pinnaró P, Terzoli E, Giannarelli D.
    Am J Clin Oncol; 1989 Dec; 12(6):524-9. PubMed ID: 2589233
    [Abstract] [Full Text] [Related]

  • 6. Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF.
    Roila F, Tonato M, Basurto C, Minotti V, Ballatori E, del Favero A.
    Eur J Cancer Clin Oncol; 1987 Jun; 23(6):615-7. PubMed ID: 3308477
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
    Levitt M, Warr D, Yelle L, Rayner HL, Lofters WS, Perrault DJ, Wilson KS, Latreille J, Potvin M, Warner E.
    N Engl J Med; 1993 Apr 15; 328(15):1081-4. PubMed ID: 8455665
    [Abstract] [Full Text] [Related]

  • 9. High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study.
    Gez E, Warner-Efraty E, Ben-Yosef R, Ben-Baruch N, Yitzhaki N, Uziely B, Brufman G, Biran S.
    Oncology; 1987 Apr 15; 44(4):237-9. PubMed ID: 3614813
    [Abstract] [Full Text] [Related]

  • 10. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
    Buser KS, Joss RA, Piquet D, Aapro MS, Cavalli F, Haefliger JM, Jungi WF, Bauer J, Obrist R, Brunner KW.
    Ann Oncol; 1993 Jun 15; 4(6):475-9. PubMed ID: 8353089
    [Abstract] [Full Text] [Related]

  • 11. High-dose metoclopramide and dexamethasone as an antiemetic in chemotherapy of breast cancer.
    Gez E, Goodman S, Isacson R, Gerra C, Sulkes A.
    Oncology; 1986 Jun 15; 43(3):173-5. PubMed ID: 3754627
    [Abstract] [Full Text] [Related]

  • 12. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J, Chevallier B, Metz R, Fargeot P, Pujade-Lauraine E, Spielmann M, Tubiana-Hulin M, Paes D, Bons J.
    J Clin Oncol; 1990 Jun 15; 8(6):1063-9. PubMed ID: 2140854
    [Abstract] [Full Text] [Related]

  • 13. An audit of antiemetic use with CMF chemotherapy.
    Brown RS, Brown TK, Hoare D, Gaze MN.
    Clin Oncol (R Coll Radiol); 1998 Jun 15; 10(5):313-7. PubMed ID: 9848332
    [Abstract] [Full Text] [Related]

  • 14. [Antiemetic treatments associated with antineoplastic chemotherapy].
    Tres Sánchez A, Sáez Martínez MJ, Mayordomo Cámara JJ, Guillén Lloveria G, Sáenz Cusi A.
    An Med Interna; 1990 May 15; 7(5):229-32. PubMed ID: 2102716
    [Abstract] [Full Text] [Related]

  • 15. Antiemetic prophylaxis with ondansetron and methylprednisolone vs metoclopramide and methylprednisolone in mild and moderately emetogenic chemotherapy.
    Tsavaris NB, Koufos C, Katsikas M, Dimitrakopoulos A, Athanasiou E, Linardaki G.
    J Pain Symptom Manage; 1999 Sep 15; 18(3):218-22. PubMed ID: 10517044
    [Abstract] [Full Text] [Related]

  • 16. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
    Bosnjak SM, Nesković-Konstantinović ZB, Radulović SS, Susnjar S, Mitrovi LB.
    J Chemother; 2000 Oct 15; 12(5):446-53. PubMed ID: 11128567
    [Abstract] [Full Text] [Related]

  • 17. [Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen].
    Domaradzka-Woźniak A, Wojtacki J, Dziewulska-Bokiniec A.
    Przegl Lek; 1994 Oct 15; 51(5):203-5. PubMed ID: 7938648
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the antiemetic activity of bromopride in cancer patients treated with i.v. CMF.
    Roila F, Minotti V, Ballatori E, Basurto C, Tonato M.
    Tumori; 1985 Oct 31; 71(5):455-8. PubMed ID: 3840612
    [Abstract] [Full Text] [Related]

  • 19. Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.
    Barrenetxea G, Schneider J, Centeno MM, Romero H, de la Rica M, Rodríguez-Escudero FJ.
    Cancer Chemother Pharmacol; 1996 Oct 31; 38(5):471-5. PubMed ID: 8765442
    [Abstract] [Full Text] [Related]

  • 20. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma.
    Wilcox PM, Fetting JH, Nettesheim KM, Abeloff MD.
    Cancer Treat Rep; 1982 Aug 31; 66(8):1601-4. PubMed ID: 7049385
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.